Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GYS1 | P13807 | 17/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760303 | 0.95 | GYS1 (0.38) | GYS1RXRANR1H2NR1H3ALDH1A1 | |
| SCHEMBL1760531 | 0.93 | GYS1 (0.45) | GYS1 | |
| SCHEMBL12635229 | 0.87 | NR1H2 (0.39) | RXRANR1H2NR1H3ALDH1A1 | |
| SCHEMBL1760492 | 0.86 | GYS1 (0.44) | GYS1SCN9ARXRANR1H2NR1H3 | |
| SCHEMBL1760550 | 0.82 | GYS1 (0.38) | GYS1RXRANR1H2NR1H3 | |
| SCHEMBL1876952 | 0.82 | GYS1 (0.37) | GYS1SCN9ARXRANR1H2NR1H3 | |
| SCHEMBL1876954 | 0.82 | GYS1 (0.37) | GYS1SCN9ARXRANR1H2NR1H3 | |
| SCHEMBL1881813 | 0.82 | GYS1 (0.37) | GYS1SCN9ARXRANR1H2NR1H3 | |
| SCHEMBL1760374 | 0.81 | GYS1 (0.44) | GYS1RXRANR1H2NR1H3 | |
| SCHEMBL1760323 | 0.80 | PRKCZ (0.35) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011057993-A1 | INDAZOLONE DERIVATIVES AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | GYS1 2/4885SCN9A 2201/4885RXRA 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.